OTCMKTS:DNDNQ Dendreon (DNDNQ) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free DNDNQ Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dendreon alerts: Email Address Ad Behind the MarketsThe World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!Get the name of the stock here >>> About Dendreon Stock (OTCMKTS:DNDNQ)Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company’s product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.Read More Ad Behind the MarketsThe World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!Get the name of the stock here >>> DNDNQ Stock News HeadlinesDecember 19, 2023 | bbc.comWho is House of Fraser's Yuan Yafei?October 21, 2023 | thestreet.comWhy Dendreon (DNDN) Stock Hit a One-Year Low TodayApril 25, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!September 27, 2023 | jp.reuters.comBB Biotech AGJuly 12, 2023 | thestreet.comThe Next Chapter in Dendreon's Troubled History: Chapter 11 BankruptcyJune 5, 2023 | thestreet.comDendreon Stock Hits New 52-Week Low (DNDN)April 22, 2023 | thestreet.comDendreon Stock Gaps Down On Today's Open (DNDN)February 23, 2023 | thestreet.comDendreon Will Run on Provenge OK: PollApril 25, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!February 10, 2023 | thestreet.comDendreon: Biotech Stock MailbagFebruary 7, 2023 | thestreet.comDendreon Readies Cost-Cutting PlanJanuary 14, 2023 | thestreet.comSAC Upped Dendreon Exposure Before BlowupSeptember 8, 2022 | thestreet.comDendreon, Ulta Beauty: After-Hours TradingSeptember 7, 2022 | thestreet.comDendreon Shares Roiled by Medicare QuestionsSeptember 6, 2022 | thestreet.comDendreon, Vion and Allos: Biotech MailbagFebruary 12, 2022 | thestreet.comJim Cramer Answers Questions on Dendreon, Salesforce and YelpSeptember 16, 2021 | prnewswire.comAeroSafe Global Appoints Rick Lozano as Chief Commercial Officer - PRNewswireSeptember 8, 2021 | bizjournals.comBolt Biotherapeutics, Bristol-Myers Squibb sign cancer immunotherapy deal - San Francisco Business Times - San Francisco Business TimesSeptember 7, 2021 | streetinsider.comImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives - StreetInsider.comSeptember 7, 2021 | finance.yahoo.comImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives - Yahoo FinanceSee More Headlines Receive DNDNQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dendreon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2014Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:DNDNQ Previous SymbolNASDAQ:DNDN CUSIPN/A CIKN/A Webwww.dendreon.com Phone+1-206-2197815FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report DNDNQ Stock Analysis - Frequently Asked Questions How were Dendreon's earnings last quarter? Dendreon Corporation (OTCMKTS:DNDNQ) issued its quarterly earnings results on Monday, November, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biotechnology company had revenue of $73.10 million for the quarter, compared to the consensus estimate of $78.72 million. Dendreon's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.44) EPS. How do I buy shares of Dendreon? Shares of DNDNQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DNDNQ) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dendreon Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
